Windtree Therapeutics, Inc. – NASDAQ:WINT
Windtree Therapeutics stock price today
$0.481
+0.17
+55.23%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 8 hours
Windtree Therapeutics stock price monthly change
-91.89%
month
Windtree Therapeutics stock price quarterly change
-91.89%
quarter
Windtree Therapeutics stock price yearly change
-57.53%
year
Windtree Therapeutics key metrics
Market Cap | 2.90M |
Enterprise value | N/A |
P/E | -0.08 |
EV/Sales | N/A |
EV/EBITDA | 0.06 |
Price/Sales | N/A |
Price/Book | 0.16 |
PEG ratio | N/A |
EPS | 18.15 |
Revenue | N/A |
EBITDA | -17.81M |
Income | -5.96M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeWindtree Therapeutics stock price history
Windtree Therapeutics stock forecast
Windtree Therapeutics financial statements
| Jun 2023 | 0 | -6.60M | |
|---|---|---|---|
| Sep 2023 | 0 | -4.42M | |
| Dec 2023 | 0 | -5.15M | |
| Mar 2024 | 0 | 10.21M |
| Mar 2024 | 0 | 10.21M | |
|---|---|---|---|
| Sep 2025 | 3.2M | -502.19K | -15.69% |
| Dec 2025 | 3.8M | 102.96K | 2.71% |
| Dec 2025 | 3.8M | 167.39K | 4.41% |
Analysts Price target
Financials & Ratios estimates
| 2022-08-11 | -9 | -10 |
|---|---|---|
| 2022-11-14 | -13 | -6.5 |
| Jun 2023 | 40575000 | 28.97M | 71.4% |
|---|---|---|---|
| Sep 2023 | 36057000 | 28.57M | 79.24% |
| Dec 2023 | 32406000 | 29.01M | 89.54% |
| Mar 2024 | 30103000 | 14.68M | 48.77% |
| Jun 2023 | -3.49M | 0 | 10.71M |
|---|---|---|---|
| Sep 2023 | -3.85M | -15K | -233K |
| Dec 2023 | -3.56M | 0 | 521K |
| Mar 2024 | -2.94M | 0 | 1.03M |
Windtree Therapeutics alternative data
| Aug 2023 | 20 |
|---|---|
| Sep 2023 | 20 |
| Oct 2023 | 20 |
| Nov 2023 | 20 |
| Dec 2023 | 20 |
| Jan 2024 | 20 |
| Feb 2024 | 20 |
| Apr 2024 | 20 |
| May 2024 | 20 |
| Jun 2024 | 20 |
| Jul 2024 | 20 |
Windtree Therapeutics other data
1.09%
-20.52%
of WINT is owned by hedge funds
1.57K
-29.51K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2023 | 2812 | 0 |
| Sep 2023 | 5000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | FRASER CRAIG director, officer.. | Common Stock | 2,500 | $1.02 | $2,550 | ||
Purchase | FRASER CRAIG director, officer.. | Common Stock | 2,500 | $0.9 | $2,250 | ||
Purchase | FRASER CRAIG director, officer.. | Common Stock | 1,497 | $1.77 | $2,650 | ||
Purchase | FRASER CRAIG director, officer.. | Common Stock | 1,315 | $1.89 | $2,485 | ||
Purchase | FRASER CRAIG director, officer.. | Common Stock | 2,500 | $0.38 | $950 | ||
Purchase | FRASER CRAIG director, officer.. | Common Stock | 2,500 | $0.37 | $935 | ||
Purchase | HAMILL JOHN P. officer: SVP & CFO | Common Stock | 3,000 | $0.37 | $1,101 | ||
Purchase | HAMILL JOHN P. officer: SVP & CFO | Common Stock | 3,000 | $0.37 | $1,101 | ||
Purchase | FRASER CRAIG director, officer.. | Common Stock | 4,500 | $0.43 | $1,926 | ||
Purchase | FRASER CRAIG director, officer.. | Common Stock | 7,000 | $0.42 | $2,905 |
| Quarter | Transcript |
|---|---|
| Q1 2016 12 May 2016 | Q1 2016 Earnings Call Transcript |
| Q4 2015 24 Mar 2016 | Q4 2015 Earnings Call Transcript |
| Q2 2015 11 Aug 2015 | Q2 2015 Earnings Call Transcript |
| Q4 2014 17 Mar 2015 | Q4 2014 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Craig E. Fraser (1965) Pres, Chief Executive Officer & Director | $769,960 |
Mr. Eric L. Curtis M.B.A. (1968) Senior Vice President & Chief Operating Officer | $526,250 |
| Mr. John P. Hamill (1964) Senior Vice President, Chief Financial Officer & Corporation Sec. | $463,550 |
-
What's the price of Windtree Therapeutics stock today?
One share of Windtree Therapeutics stock can currently be purchased for approximately $0.48.
-
When is Windtree Therapeutics's next earnings date?
Unfortunately, Windtree Therapeutics's (WINT) next earnings date is currently unknown.
-
Does Windtree Therapeutics pay dividends?
No, Windtree Therapeutics does not pay dividends.
-
How much money does Windtree Therapeutics make?
Windtree Therapeutics has a market capitalization of 2.90M. Windtree Therapeutics made a loss 20.29M US dollars in net income (profit) last year or -$6.5 on an earnings per share basis.
-
What is Windtree Therapeutics's stock symbol?
Windtree Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "WINT".
-
What is Windtree Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Windtree Therapeutics?
Shares of Windtree Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Windtree Therapeutics's key executives?
Windtree Therapeutics's management team includes the following people:
- Mr. Craig E. Fraser Pres, Chief Executive Officer & Director(age: 60, pay: $769,960)
- Mr. Eric L. Curtis M.B.A. Senior Vice President & Chief Operating Officer(age: 57, pay: $526,250)
- Mr. John P. Hamill Senior Vice President, Chief Financial Officer & Corporation Sec.(age: 61, pay: $463,550)
-
How many employees does Windtree Therapeutics have?
As Jul 2024, Windtree Therapeutics employs 20 workers.
-
When Windtree Therapeutics went public?
Windtree Therapeutics, Inc. is publicly traded company for more then 30 years since IPO on 7 Aug 1995.
-
What is Windtree Therapeutics's official website?
The official website for Windtree Therapeutics is windtreetx.com.
-
Where are Windtree Therapeutics's headquarters?
Windtree Therapeutics is headquartered at 2600 Kelly Road, Warrington, PA.
-
How can i contact Windtree Therapeutics?
Windtree Therapeutics's mailing address is 2600 Kelly Road, Warrington, PA and company can be reached via phone at 215 488 9300.
Windtree Therapeutics company profile:
Windtree Therapeutics, Inc.
windtreetx.comExchange:
NASDAQ
Full time employees:
20
Industry:
Biotechnology
Sector:
Healthcare
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
2600 Kelly Road
Warrington, PA 18976-3622
Warrington, PA 18976-3622
CIK: 0000946486
ISIN: US97382D4025
CUSIP: 97382D303
